{"schema":"sb.node.v1","id":"sb:e/c6b4f78a4499a8ee5995162f","kind":"entity","label":{"text":"drug discovery","locale":"en"},"identity":{"anchor":"label:en:drug discovery","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy ca6a7ff4ea5f1023d32744319b6e6bb3d9adc15f"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":203,"separatePublishers":81,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-19","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.172: about 83% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","quantum_computing"],"activeDays":41,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/10dfa73582f98ef05bde95ee","kind":"observation","label":"STAT News · 2026-10-08 · STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines","url":"https://www.statnews.com/2026/10/08/roche-defand-therapeutics-drug-development-deal/?utm_campaign=rss"},{"id":"sb:o/39f5ea425a94154612c66732","kind":"observation","label":"The Medical News · 2026-10-08 · Protein sciences in drug discovery 2026","url":"https://www.news-medical.net/news/20261008/Protein-sciences-in-drug-discovery-2026.aspx"},{"id":"sb:o/eb174cca5b31cde21f4302c4","kind":"observation","label":"Clinical Trials Arena · 2026-10-07 · How advances in drug discovery are changing the path from research to clinical trials","url":"https://www.clinicaltrialsarena.com/comment/how-advances-in-drug-discovery-are-changing-the-path-from-research-to-clinical-trials/"},{"id":"sb:o/d7ffe89a57b6b1afd03984d4","kind":"observation","label":"AllSci News · 2026-10-06 · Italfarmaco and VeriSIM Life combine AI and HDAC expertise in USD 100m+ drug discovery deal","url":"https://allsci.com/news/biotech/hdac-drug-discovery-italfarmaco-and-verisim-life/"},{"id":"sb:o/79009a0d57d92578aba74b92","kind":"observation","label":"The Medical News · 2026-10-05 · BioDuro appoints Greg Makara as Senior Vice President Lead Discovery Chemistry to strengthen early drug discovery capabilities","url":"https://www.news-medical.net/news/20261005/BioDuro-appoints-Greg-Makara-as-Senior-Vice-President-Lead-Discovery-Chemistry-to-strengthen-early-drug-discovery-capabilities.aspx"},{"id":"sb:o/46fb01cd514002e99e14a40f","kind":"observation","label":"AllSci News · 2026-10-01 · Novartis and CAS build reaction-data backbone for AI drug discovery","url":"https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-platform-cas-and-novartis/"},{"id":"sb:o/10f26c9e51f13a32368da50f","kind":"observation","label":"Fierce Biotech · 2026-10-01 · Accelerating scientific innovation and discovery: How AI is transforming the future of drug discovery, development and manufacturing","url":"https://www.fiercebiotech.com/resource/accelerating-scientific-innovation-and-discovery-how-ai-transforming-future-drug-discovery"},{"id":"sb:o/a8a7a60a7d6b4e223bf686a4","kind":"observation","label":"SiliconANGLE · 2026-09-28 · Qiagen grounds drug discovery agents in curated knowledge","url":"https://siliconangle.com/2026/09/28/qiagen-grounds-ai-drug-discovery-agents-curated-knowledge-neo4jgraphsummit/"},{"id":"sb:o/677bf829486c658d83f54482","kind":"observation","label":"Tekedia · 2026-09-25 · Lilly Signs Up to $3.35 Billion Drug Discovery Deal With China’s InnoCare","url":"https://www.tekedia.com/lilly-signs-up-to-3-35-billion-drug-discovery-deal-with-chinas-innocare/"},{"id":"sb:o/ac02f3f088098b1fbf8fc247","kind":"observation","label":"Pulse 2.0 · 2026-09-25 · AbbVie And Iambic Partner To Accelerate AI-Driven Drug Discovery In Immunology, Neuroscience And Oncology","url":"https://pulse2.com/abbvie-and-iambic-partner-to-accelerate-ai-driven-drug-discovery-in-immunology-neuroscience-and-oncology/"}],"cursor":"c1.eyJpZCI6InNiOmUvYzZiNGY3OGE0NDk5YThlZTU5OTUxNjJmIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with ai (136 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cac4d908dc672badb3c25ab0"},{"kind":"relation","label":"co-mentioned with studie (45 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/40a763ff46775923e9e7f869"},{"kind":"relation","label":"co-mentioned with clinical trials (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dd5ffb860ed17a8a98f4e595"},{"kind":"relation","label":"co-mentioned with quantum computing (40 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b25b5768e0cc4c1a18861434"},{"kind":"relation","label":"co-mentioned with fda (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5ee2cad3188b6a2c929b12e5"},{"kind":"relation","label":"co-mentioned with drug development (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/44fcb2b4862df926d560451d"},{"kind":"relation","label":"co-mentioned with size (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/930c856b1ccf5b55af1ee75b"},{"kind":"relation","label":"co-mentioned with united states (30 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0fd39d2f1855a8e748c9c5b4"},{"kind":"relation","label":"co-mentioned with nvidia (28 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/50740511aa3151b1145662f7"},{"kind":"relation","label":"co-mentioned with china (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9f62d598805291e1728e4715"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/c6b4f78a4499a8ee5995162f","mcp":"traverse {\"id\":\"sb:e/c6b4f78a4499a8ee5995162f\"}","page":"/entity/drug-discovery/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c6b4f78a4499a8ee5995162f\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c6b4f78a4499a8ee5995162f\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c6b4f78a4499a8ee5995162f\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c6b4f78a4499a8ee5995162f\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}